Exforge(R) : truly forging new ground?
Metadata[+] Show full item record
Exforge(R) is a new medication combining amlodipine (Norvasc(R)), a well-known dihydropyridine calcium channel blocker (CCB), and valsartan (Diovan(R)), an angiotensin receptor blocker (ARB). This is the first product to combine these 2 classes of medication; however, other antihypertensive products have combined a CCB with an angiotensin-converting enzyme inhibitor (ACEI). Advantages of combination antihypertensive products include decreased pill burden, simplified dosing regimen, and fewer side effects due to potential lower doses of each medication. However, combination dosage formulations do not allow for precise dose titration, and adverse effects are difficult to attribute to an individual agent.
Evidence-based practice 11, no. 04 (2008): 10+